Save Product
Product Details
Specificity
This product is a specific antibody specifically reacts with Eribulin.
Source
Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M2B11) is a Rabbit monoclonal antibody recombinantly expressed from HEK293 cells.
Clone
1M2B11
Isotype
Rabbit IgG | Rabbit Kappa
Conjugate
Unconjugated
Application
ApplicationRecommended UsageELISA0.2-125 ng/mLPurification
Protein A purified / Protein G purified
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M2B11) (Cat. No. ERN-MY2063b) at 1 μg/mL, add Farletuzumab Ecteribulin in the 100% Human Serum and then add Biotinylated Human FOLR1, Fc,Avitag (Cat. No. FO1-H82F9) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).
Protocol
Immobilized Farletuzumab Ecteribulin at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M2B11) (Cat. No. ERN-MY2063b) with a linear range of 0.06-2 ng/mL (Routinely tested).
Protocol
Serial dilutions of Eribulin were added into Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M2B11) (Cat. No. ERN-MY2063b): Farletuzumab ecteribulin binding reactions. The half maximal inhibitory concentration (IC50) is 0.5451 μg/mL (Routinely tested).
Protocol
Cross Verification
ELISA binding of Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M2B11) (Cat. No. ERN-MY2063b) with Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam, Farletuzumab Ecteribulin, IgG1-MMAF and Trastuzumab-DM1 conjugated antibody respectively.
The coating antibody was Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M2B11) (Cat. No. ERN-MY2063b), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam, Farletuzumab Ecteribulin, IgG1-MMAF and Trastuzumab-DM1 conjugated antibodies used at 0.5 μg/mL concentration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8), mAb (Acro, Cat. No. IGG-LY69) used at 1:10000 concentration.
Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M2B11) (Cat. No. ERN-MY2063b) is specific to Farletuzumab Ecteribulin, and has no cross-reactivity with Trastuzumab Deruxtecan, Sacituzumab Govitecam, Disitamab Vedotin (RC48), IgG1-MMAF and Trastuzumab-DM1 (Routinely tested).
Customer Reviews Writing Reviews
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing